Loading...
4105 logo

TTY Biopharm Company LimitedTPEX:4105 Stock Report

Market Cap NT$19.5b
Share Price
n/a
1Y2.5%
7D1.4%
1D-0.1%
Portfolio Value
​
View

TTY Biopharm Company Limited

TPEX:4105 Stock Report

Market Cap: NT$19.5b

TTY Biopharm (4105) Stock Overview

Engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. More details

4105 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends5/6

Rewards

Trading at 72.1% below our estimate of its fair value

Earnings have grown 15.4% per year over the past 5 years

Risk Analysis

Unstable dividend track record


4105 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW424,136 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
424,136 investors already sharing narratives
View all narratives

TTY Biopharm Company Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for TTY Biopharm
Historical stock prices
Current Share PriceNT$78.50
52 Week HighNT$87.00
52 Week LowNT$71.60
Beta0.12
1 Month Change2.75%
3 Month Change6.80%
1 Year Change2.48%
3 Year Change2.88%
5 Year Change3.97%
Change since IPO1,197.36%

Recent News & Updates

Recent updates

Analysis Article • Apr 02

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Mar 15

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Today we will run through one way of estimating the intrinsic value of TTY Biopharm Company Limited ( GTSM:4105 ) by...
Analysis Article • Feb 25

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Could TTY Biopharm Company Limited ( GTSM:4105 ) be an attractive dividend share to own for the long haul? Investors...
Analysis Article • Feb 07

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

With its stock down 11% over the past three months, it is easy to disregard TTY Biopharm (GTSM:4105). However, stock...
Analysis Article • Jan 19

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

The latest analyst coverage could presage a bad day for TTY Biopharm Company Limited ( GTSM:4105 ), with the analysts...
Analysis Article • Jan 10

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
Analysis Article • Dec 15

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Nov 25

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Dividend paying stocks like TTY Biopharm Company Limited (GTSM:4105) tend to be popular with investors, and for good...

Shareholder Returns

4105TW PharmaceuticalsTW Market
7D1.4%-0.2%-2.8%
1Y2.5%-33.5%78.2%

Return vs Industry: 4105 exceeded the TW Pharmaceuticals industry which returned -33.5% over the past year.

Return vs Market: 4105 underperformed the TW Market which returned 78.2% over the past year.

Price Volatility

Is 4105's price volatile compared to industry and market?
4105 volatility
4105 Average Weekly Movement2.1%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement5.8%
10% most volatile stocks in TW Market11.2%
10% least volatile stocks in TW Market2.4%

Stable Share Price: 4105 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 4105's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1960n/an/awww.tty.com.tw

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Yondelis, Pemazyre, Pulmivex, Xpovio, Minjuvi, and Fustron names.

TTY Biopharm Company Limited Fundamentals Summary

How do TTY Biopharm's earnings and revenue compare to its market cap?
4105 fundamental statistics
Market capNT$19.54b
Earnings (TTM)NT$1.73b
Revenue (TTM)NT$6.65b
11.3x
P/E Ratio
2.9x
P/S Ratio

Is 4105 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4105 income statement (TTM)
RevenueNT$6.65b
Cost of RevenueNT$2.82b
Gross ProfitNT$3.83b
Other ExpensesNT$2.10b
EarningsNT$1.73b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)6.97
Gross Margin57.57%
Net Profit Margin26.04%
Debt/Equity Ratio26.5%

How did 4105 perform over the long term?

See historical performance and comparison

Dividends

5.7%
Current Dividend Yield
65%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/17 14:19
End of Day Share Price 2026/09/17 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TTY Biopharm Company Limited is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christine WangDaiwa Securities Co. Ltd.
Caren HuangJ.P. Morgan
Yu-Ying YangKGI Securities Co. Ltd.